Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Hims & Hers is shutting down Apostrophe, the skincare company it acquired in 2021, after a tumultuous month for the public ...

Hims & Hers Health ( HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% ...

Back in May, Hims & Hers started selling compounded semaglutide — the active ingredient in Novo Nordisk’s (NVO) Ozempic and Wegovy — for just $199 a month. That’s a big difference compared ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

BofA analyst Allen Lutz notes that the Food and Drug Administration yesterday provided updated enforcement timelines for semaglutide and ...

That means compounding of semaglutide will no longer be permitted under current regulations. Shares of Hims & Hers plummeted 25% on Friday following the FDA announcement. The company's stock is up ...

Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on ...

The company's chief financial officer, Yemi Okupe, confirmed after Hims & Hers' fourth-quarter earnings that the company planned to remove all commercially available doses of semaglutide from its ...

However, the stock gave back a lot of gains after semaglutide, the active ingredient in GLP-1 weight loss drug Ozempic, was taken off the Food & Drug Administration's shortage list. Hims & Hers ...